-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $15

Benzinga·05/15/2026 11:34:36
Listen to the news
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $18 to $15.